secwatch.observer — SEC 8-K summary
======================================

Issuer:     RESMED INC (RMD)
CIK:        0000943819
Form:       8-K
Filed at:   2022-06-14T23:59:59+00:00
Accession:  0001193125-22-173521
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ResMed to acquire German out-of-hospital software leader MEDIFOX DAN for ~$1B
-----------------------------------------------------------------------------

- Purchase price ~US$1.0B (€950M); expected to close by Dec 31, 2022 subject to German regulatory clearances.
- MEDIFOX DAN CY2021 pro forma revenue ~$83M, adjusted EBITDA ~$35M; deal expected accretive to non-GAAP EPS.
- Expands ResMed's SaaS business into Germany; MEDIFOX DAN brand and management to continue under ResMed SaaS.
- Co-managing directors Dr. Thorsten Schliebe and Christian Städtler will remain, reporting to ResMed SaaS President.
- ResMed to fund via existing credit facilities; Evercore and DLA Piper serving as advisors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/943819/000119312522173521/0001193125-22-173521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/943819/000119312522173521/d366389d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-173521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer